Cargando…
N-acetylcysteine as an add-on to Directly Observed Therapy Short-I therapy in fresh pulmonary tuberculosis patients: A randomized, placebo-controlled, double-blinded study
PURPOSE: Pulmonary tuberculosis is associated with increased oxidative stress, enhanced lipid peroxidation, and decreased glutathione (GSH) levels. N-acetylcysteine (NAC) effectively increases GSH levels, improves lipid peroxidation, and decreases reactive oxygen species levels as reported by earlie...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543764/ https://www.ncbi.nlm.nih.gov/pubmed/28828308 http://dx.doi.org/10.4103/2229-3485.210450 |
_version_ | 1783255207669399552 |
---|---|
author | Mahakalkar, Sunil M. Nagrale, Dinesh Gaur, Sanjay Urade, Chetan Murhar, Bhalchandra Turankar, Avinash |
author_facet | Mahakalkar, Sunil M. Nagrale, Dinesh Gaur, Sanjay Urade, Chetan Murhar, Bhalchandra Turankar, Avinash |
author_sort | Mahakalkar, Sunil M. |
collection | PubMed |
description | PURPOSE: Pulmonary tuberculosis is associated with increased oxidative stress, enhanced lipid peroxidation, and decreased glutathione (GSH) levels. N-acetylcysteine (NAC) effectively increases GSH levels, improves lipid peroxidation, and decreases reactive oxygen species levels as reported by earlier studies. Hence, we planned to clinically evaluate the effect of NAC as add-on to Directly Observed Therapy Short-I (DOTS-I) regimen on treatment outcome in PTB with the objectives to study the effect of NAC as an add-on to intensive phase of DOTS-I (2 months) on sputum conversion, radiological improvement, GSH peroxidase (GPx) level, and weight and immunological response compared to placebo add-on at the end of 2 and 6 months. MATERIALS AND METHODS: This was a design-prospective, randomized, parallel group, add-on design, placebo-controlled, double-blinded, 24-week study. Parameters studied were sputum acid-fast bacillus examination, radiological improvements, GPx level, weight, and Mantoux response. NAC/placebo was added to DOTS Category I in intensive phase. RESULTS: Totally 48 patients completed the study. In NAC group, 23 patients achieved sputum negativity in 3 weeks while 14 patients in PLACEBO group. There was a significant clearing of infiltration and reduction in cavity size in NAC group compared to placebo at 2 months. At 2 and 6 months, NAC significantly raised GPx level and body weight. In 2 months, the patients with Mix ≤5 became Mx positive (100%) in NAC group while none in placebo group. CONCLUSION: NAC addition to DOTS-I significantly brings about faster sputum negativity, improves radiological response, weight, raises serum GPx level, and rectifies the deregulated immune response. Thus, NAC may be a useful adjuvant to DOTS in PTB. |
format | Online Article Text |
id | pubmed-5543764 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-55437642017-08-21 N-acetylcysteine as an add-on to Directly Observed Therapy Short-I therapy in fresh pulmonary tuberculosis patients: A randomized, placebo-controlled, double-blinded study Mahakalkar, Sunil M. Nagrale, Dinesh Gaur, Sanjay Urade, Chetan Murhar, Bhalchandra Turankar, Avinash Perspect Clin Res Original Article PURPOSE: Pulmonary tuberculosis is associated with increased oxidative stress, enhanced lipid peroxidation, and decreased glutathione (GSH) levels. N-acetylcysteine (NAC) effectively increases GSH levels, improves lipid peroxidation, and decreases reactive oxygen species levels as reported by earlier studies. Hence, we planned to clinically evaluate the effect of NAC as add-on to Directly Observed Therapy Short-I (DOTS-I) regimen on treatment outcome in PTB with the objectives to study the effect of NAC as an add-on to intensive phase of DOTS-I (2 months) on sputum conversion, radiological improvement, GSH peroxidase (GPx) level, and weight and immunological response compared to placebo add-on at the end of 2 and 6 months. MATERIALS AND METHODS: This was a design-prospective, randomized, parallel group, add-on design, placebo-controlled, double-blinded, 24-week study. Parameters studied were sputum acid-fast bacillus examination, radiological improvements, GPx level, weight, and Mantoux response. NAC/placebo was added to DOTS Category I in intensive phase. RESULTS: Totally 48 patients completed the study. In NAC group, 23 patients achieved sputum negativity in 3 weeks while 14 patients in PLACEBO group. There was a significant clearing of infiltration and reduction in cavity size in NAC group compared to placebo at 2 months. At 2 and 6 months, NAC significantly raised GPx level and body weight. In 2 months, the patients with Mix ≤5 became Mx positive (100%) in NAC group while none in placebo group. CONCLUSION: NAC addition to DOTS-I significantly brings about faster sputum negativity, improves radiological response, weight, raises serum GPx level, and rectifies the deregulated immune response. Thus, NAC may be a useful adjuvant to DOTS in PTB. Medknow Publications & Media Pvt Ltd 2017 /pmc/articles/PMC5543764/ /pubmed/28828308 http://dx.doi.org/10.4103/2229-3485.210450 Text en Copyright: © 2017 Perspectives in Clinical Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Mahakalkar, Sunil M. Nagrale, Dinesh Gaur, Sanjay Urade, Chetan Murhar, Bhalchandra Turankar, Avinash N-acetylcysteine as an add-on to Directly Observed Therapy Short-I therapy in fresh pulmonary tuberculosis patients: A randomized, placebo-controlled, double-blinded study |
title | N-acetylcysteine as an add-on to Directly Observed Therapy Short-I therapy in fresh pulmonary tuberculosis patients: A randomized, placebo-controlled, double-blinded study |
title_full | N-acetylcysteine as an add-on to Directly Observed Therapy Short-I therapy in fresh pulmonary tuberculosis patients: A randomized, placebo-controlled, double-blinded study |
title_fullStr | N-acetylcysteine as an add-on to Directly Observed Therapy Short-I therapy in fresh pulmonary tuberculosis patients: A randomized, placebo-controlled, double-blinded study |
title_full_unstemmed | N-acetylcysteine as an add-on to Directly Observed Therapy Short-I therapy in fresh pulmonary tuberculosis patients: A randomized, placebo-controlled, double-blinded study |
title_short | N-acetylcysteine as an add-on to Directly Observed Therapy Short-I therapy in fresh pulmonary tuberculosis patients: A randomized, placebo-controlled, double-blinded study |
title_sort | n-acetylcysteine as an add-on to directly observed therapy short-i therapy in fresh pulmonary tuberculosis patients: a randomized, placebo-controlled, double-blinded study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543764/ https://www.ncbi.nlm.nih.gov/pubmed/28828308 http://dx.doi.org/10.4103/2229-3485.210450 |
work_keys_str_mv | AT mahakalkarsunilm nacetylcysteineasanaddontodirectlyobservedtherapyshortitherapyinfreshpulmonarytuberculosispatientsarandomizedplacebocontrolleddoubleblindedstudy AT nagraledinesh nacetylcysteineasanaddontodirectlyobservedtherapyshortitherapyinfreshpulmonarytuberculosispatientsarandomizedplacebocontrolleddoubleblindedstudy AT gaursanjay nacetylcysteineasanaddontodirectlyobservedtherapyshortitherapyinfreshpulmonarytuberculosispatientsarandomizedplacebocontrolleddoubleblindedstudy AT uradechetan nacetylcysteineasanaddontodirectlyobservedtherapyshortitherapyinfreshpulmonarytuberculosispatientsarandomizedplacebocontrolleddoubleblindedstudy AT murharbhalchandra nacetylcysteineasanaddontodirectlyobservedtherapyshortitherapyinfreshpulmonarytuberculosispatientsarandomizedplacebocontrolleddoubleblindedstudy AT turankaravinash nacetylcysteineasanaddontodirectlyobservedtherapyshortitherapyinfreshpulmonarytuberculosispatientsarandomizedplacebocontrolleddoubleblindedstudy |